News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Merck & Co., Inc., Schering-Plough Corporation’s Vytorin Fails to Meet Main Goal of Heart Study
July 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (Reuters) - The cholesterol fighter Vytorin sold by Merck & Co Inc and Schering-Plough Corp failed to meet the main goal of improving cardiovascular outcomes in a closely-watched heart study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Postmarket research
MORE ON THIS TOPIC
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
October 23, 2025
·
3 min read
·
Tristan Manalac
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
October 22, 2025
·
4 min read
·
Tristan Manalac
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
October 22, 2025
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff
October 22, 2025
·
2 min read
·
Tristan Manalac
